Article info

Download PDFPDF

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

Authors

  1. Correspondence to Dr Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan; tanaka{at}med.uoeh-u.ac.jp
View Full Text

Citation

Tanaka Y, Takeuchi T, Tanaka S, et al
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

Publication history

  • Received January 31, 2019
  • Revised April 30, 2019
  • Accepted April 30, 2019
  • First published July 26, 2019.
Online issue publication 
September 12, 2019

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.